The stock of ENDRA Life Sciences Inc (NDRA) has gone down by -44.02% for the week, with a -32.28% drop in the past month and a -34.60% drop in the past quarter. The volatility ratio for the week is 10.81%, and the volatility levels for the past 30 days are 21.29% for NDRA. The simple moving average for the past 20 days is -25.37% for NDRA’s stock, with a -79.46% simple moving average for the past 200 days.
Is It Worth Investing in ENDRA Life Sciences Inc (NASDAQ: NDRA) Right Now?
Company’s 36-month beta value is -0.06.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NDRA is 0.56M, and currently, short sellers hold a 7.98% ratio of that floaft. The average trading volume of NDRA on May 09, 2025 was 145.33K shares.
NDRA) stock’s latest price update
The stock price of ENDRA Life Sciences Inc (NASDAQ: NDRA) has plunged by -44.07 when compared to previous closing price of 6.15, but the company has seen a -44.02% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-03-31 that ANN ARBOR, Mich.–(BUSINESS WIRE)–ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunction-associated steatohepatitis (MASH) therapies. ENDRA’s management has thoroughly evaluated the Comp.
NDRA Trading at -19.12% from the 50-Day Moving Average
After a stumble in the market that brought NDRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.43% of loss for the given period.
Volatility was left at 21.29%, however, over the last 30 days, the volatility rate increased by 10.81%, as shares sank -18.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.83% lower at present.
During the last 5 trading sessions, NDRA fell by -47.84%, which changed the moving average for the period of 200-days by -97.69% in comparison to the 20-day moving average, which settled at $4.60. In addition, ENDRA Life Sciences Inc saw -45.05% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NDRA starting from UBS Group AG, who purchase 3,715 shares at the price of $0.55 back on Aug 27 ’24. After this action, UBS Group AG now owns 146,012 shares of ENDRA Life Sciences Inc, valued at $2,052 using the latest closing price.
Stock Fundamentals for NDRA
Current profitability levels for the company are sitting at:
- -51.12 for the present operating margin
The net margin for ENDRA Life Sciences Inc stands at -54.39. The total capital return value is set at -2.81. Equity return is now at value -280.02, with -205.38 for asset returns.
Based on ENDRA Life Sciences Inc (NDRA), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -12.66.
Currently, EBITDA for the company is -11.3 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of -3.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.67.
Conclusion
In a nutshell, ENDRA Life Sciences Inc (NDRA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
